Abstract:Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive and lethal cancers worldwide. Despite negative margin resections and subsequent systemic therapy, PDAC often recurs. Additionally, most patients present with locally advanced and unresectable tumors at the time of diagnosis. Cancer-associated fibroblasts (CAFs) contribute to the highly desmoplastic tumor microenvironment (TME) and form a biophysical barrier, limiting immune cell infiltration. Moreover, CAF-secreted factors suppress the anti-tumor activity of T cells and shift cancer cells toward invasive proliferative and mesenchymal phenotypes. Therefore, targeting CAFs can enhance T-cell infiltration and improve the efficacy of T-cell based immunotherapeutic strategies. B7-H3 is an immune checkpoint molecule highly expressed on PDAC cells and CAFs. In this study, we investigate the use of Chimeric Antigen Receptor (CAR) T cells targeting B7-H3 to eliminate metastatic PDAC in a preclinical mouse model in three different settings: I. Adjuvant II. Neoadjuvant III. CAR T cell monotherapy. Our CART-B7-H3 construct includes an inducible caspase 9 (iC9) suicide gene, which allows for the controlled elimination of the CAR T cells in the event of overwhelming cytokine release syndrome. Methods: To validate the therapeutic potential of iC9.B7-H3 CAR T cells in vivo, NSG mice were orthotopically engrafted with 1x105 patient-derived PDAC6 cells and 9x105 hCAF1 cells at a ratio of 1:9, reflecting a clinically relevant model. In the adjuvant group, mice underwent surgical resection of the primary tumor (distal pancreatectomy and splenectomy) after 25 days. On days 30 and 60, they received systemic iC9.B7-H3 CAR T cell treatment (5x106). In the neoadjuvant group, mice were systemically treated with iC9.B7-H3 CAR T cells on day 19 and underwent surgical resection of the primary tumor on day 25, following another systemic CAR T cell dose on day 60. In the CAR T monotherapy group, mice received systemic iC9.B7-H3 CAR T cells on days 19 and 60. Results: In vivo, iC9.B7-H3 CAR T cells in the neoadjuvant group effectively eradicated both local and distant PDAC metastases for the length of the experiment (180 days) and significantly increased the survival (P <0.0001), indicating long-term efficacy in the treatment of PDAC metastases with no adverse side effects. In the adjuvant and CAR T monotherapy groups, iC9.B7-H3 CAR T cells effectively control tumor growth, eliminate metastases, and significantly increase survival (P=0.0018 and P=0.0007, respectively). Conclusion: These data suggest that the neoadjuvant application of iC9.B7-H3 CAR T cells may demonstrate persistent efficacy in eradicating both local and distant PDAC metastases. iC9.B7-H3 CAR T cells adjuvantly and as monotherapy achieved significant tumor control. Citation Format: Shahrzad Arya, Seyed Amir Sanatkar, Marco Ventin, Giulia Cattaneo, Cristina Martin, Gabriella Lionetto, Jingyu Jia, Feng Chen, David T. Ting, Xinhui Wang, Sandra Ryeom, Cristina R. Ferrone, Soldano Ferrone. Enhancing CAR T cell-based immunotherapy outcomes in PDAC: Evaluating iC9.B7-H3 CAR T cells in adjuvant, neoadjuvant, and monotherapy settings [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6313.

Abstract 549: The IgG4 hinge with CD28 transmembrane domain mediates CAR dimerization and improves the activity of glypican 1-targeted CAR T cells in pancreatic cancer

Abstract 4103: The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer

Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy

Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity

CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells

Abstract 6335: Armoring CAR-T therapy with PD-1 blockade: a powerful strategy for enhancing anti-tumor effects in pancreatic cancer

Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC

Chimeric Antigen Receptor Clustering Via Cysteines Enhances T-cell Efficacy Against Tumor

Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival In Vivo With Low Cytokines Release

Abstract 1204: Design and development of anti-linker antibodies for the detection and characterization of CAR T cells

Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments

Abstract 5227: Gamma-delta (γδ) CAR-T cells lacking the CD3ζ signaling domain enhance targeted killing of AML cells and preserve healthy tissues

Abstract 1780: TCR-T and CAR-T cells targeting HLA-A2/MAGEA4 demonstrate differential tumor control, reflecting co-stimulatory signaling requirements

Abstract 58: Immunocytokines with specificity for invariant region of CAR molecules enhance effector function of multiple CAR T cell therapies

Increased Antitumor Activities of Glypican-3-specific Chimeric Antigen Receptor-Modified T Cells by Coexpression of a Soluble PD1-CH3 Fusion Protein.

Abstract 4008: DASH CAR-T: accelerating CD276-targeted immunotherapy for pancreatic cancer

4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2<SUP>nd</SUP> Generation Chimeric Antigen Receptor-Modified T Cells

Abstract 3609: Chimeric cytokine receptors increase memory phenotypes and improve expansion and efficacy of CAR-T cell therapies

Harnessing CD3 diversity to optimize CAR T cells

Abstract 6313: Enhancing CAR T cell-based immunotherapy outcomes in PDAC: Evaluating iC9.B7-H3 CAR T cells in adjuvant, neoadjuvant, and monotherapy settings

Abstract 4106: Non-autonomous enhancement of gPDL1 CAR-T annihilates TNBC development